{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T07:11:58Z","timestamp":1763536318235},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,27]]},"DOI":"10.7759\/cureus.70351","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:32:24Z","timestamp":1727483544000},"source":"Crossref","is-referenced-by-count":1,"title":["Association Between Febuxostat Use and the Incidence of Cardiovascular Events, Mortality, and Kidney Events in Patients With Chronic Kidney Disease Compared to Allopurinol: A Study Using a Japanese Nationwide Database"],"prefix":"10.7759","author":[{"given":"Miho","family":"Otani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Nonomiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutaka","family":"Ihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satsuki","family":"Taniuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisako","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Tsuruya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Shintani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White WB","year":"2018","unstructured":"White WB, Saag KG, Becker MA, et al.. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018, 378:1200-1210. 10.1056\/NEJMoa1710895","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"28","author":"Mackinzie IS","year":"2020","unstructured":"Mackinzie IS, Ford I, Nuki G, et al.. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020, 28:1745-1757. 10.1016\/S0140-6736(20)32234-0","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/euroheartj\/ehz119","article-title":"Febuxostat for cerebral and cardiorenovascular events prevention study","volume":"40","author":"Kojima S","year":"2019","unstructured":"Kojima S, Matsui K, Hiramitsu S, et al.. Febuxostat for cerebral and cardiorenovascular events prevention study. Eur Heart J. 2019, 40:1778-1786. 10.1093\/euroheartj\/ehz119","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-024-02497-4","article-title":"Essential points from evidence-based clinical practice guideline for chronic kidney disease 2023","volume":"28","author":"Japanese Society of Nephrology","year":"2024","unstructured":"Japanese Society of Nephrology. Essential points from evidence-based clinical practice guideline for chronic kidney disease 2023. Clin Exp Nephrol. 2024, 28:473-495. 10.1007\/s10157-024-02497-4","journal-title":"Clin Exp Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173843","article-title":"Longitudinal change in estimated GFR among CKD patients: a 10-year follow-up study of an integrated kidney disease care program in Taiwan","volume":"12","author":"Tsai CW","year":"2017","unstructured":"Tsai CW, Ting I, Yeh HC, et al.. Longitudinal change in estimated GFR among CKD patients: a 10-year follow-up study of an integrated kidney disease care program in Taiwan. PLoS ONE. 2017, 12:0173843-10. 10.1371\/journal.pone.0173843","journal-title":"PLoS ONE"},{"key":"ref6","unstructured":"Medical Data Vision Co., Ltd. press release. updated database information 2019. [in Japanese]. (2019). Accessed: September 6, 2024: http:\/\/www.mdv.co.jp\/press\/2019\/detail_1201.html."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.37737\/ace.1.3_76","article-title":"Real-world data in Japan","volume":"1","author":"Yasunaga H","year":"2019","unstructured":"Yasunaga H. Real-world data in Japan. Ann Clin Epidemiol. 2019, 1:76-79. 10.37737\/ace.1.3_76","journal-title":"Ann Clin Epidemiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocpiqo.2020.10.001","article-title":"Cardiovascular and renal outcomes associated with hyperkalemia in chronic kidney disease: a hospital-based cohort study","volume":"5","author":"Kohsaka S","year":"2021","unstructured":"Kohsaka S, Okami S, Kanda E, et al.. Cardiovascular and renal outcomes associated with hyperkalemia in chronic kidney disease: a hospital-based cohort study. Mayo Clin Proc Inn Qual Out. 2021, 5:274-285. 10.1016\/j.mayocpiqo.2020.10.001","journal-title":"Mayo Clin Proc Inn Qual Out"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.37737\/ace.22004","article-title":"Validation study of algorithms to identify malignant tumors and serious infections in a Japanese administrative healthcare database","volume":"4","author":"Nishikawa A","year":"2022","unstructured":"Nishikawa A, Yoshinaga E, Nakamura M, et al.. Validation study of algorithms to identify malignant tumors and serious infections in a Japanese administrative healthcare database. Annals Clin Epidemiol. 2022, 4:20-23. 10.37737\/ace.22004","journal-title":"Annals Clin Epidemiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial","volume":"72","author":"Kimura K","year":"2018","unstructured":"Kimura K, Hosoya T, Uchida S, et al.. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. AJKD. 2018, 72:798-810. 10.1053\/j.ajkd.2018.06.028","journal-title":"AJKD"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008121270","article-title":"Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes","volume":"20","author":"Ninomiya T","year":"2009","unstructured":"Ninomiya T, Perkovic V, de Galan B, et al.. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009, 20:1813-1821. 10.1681\/ASN.2008121270","journal-title":"J Am Soc Nephrol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.51518","article-title":"Early-stage chronic kidney disease and related health care spending","volume":"7","author":"Sakoi N","year":"2024","unstructured":"Sakoi N, Mori Y, Tsugawa Y, et al.. Early-stage chronic kidney disease and related health care spending. JAMA Netw Open. 2024, 7:2351518. 10.1001\/jamanetworkopen.2023.51518","journal-title":"JAMA Netw Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/292255-association-between-febuxostat-use-and-the-incidence-of-cardiovascular-events-mortality-and-kidney-events-in-patients-with-chronic-kidney-disease-compared-to-allopurinol-a-study-using-a-japanese-nationwide-database","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:32:27Z","timestamp":1727483547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/292255-association-between-febuxostat-use-and-the-incidence-of-cardiovascular-events-mortality-and-kidney-events-in-patients-with-chronic-kidney-disease-compared-to-allopurinol-a-study-using-a-japanese-nationwide-database"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.70351","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,27]]}}}